An ongoing first-in-human phase 1 trial of NX-5948, an oral Bruton's tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B cell malignancies, including chronic lymphocytic leukemia (CLL)

Francesco Forconi; Graham Collins; Emma Searle; Dima El-Sharkawi; David Lewis; Mary Gleeson; John Riches; Pam Mckay; Jeanette Doorduijn; Rogier Mous; Wendy Stevens; Sarah Injac; Kim Linton

An ongoing first-in-human phase 1 trial of NX-5948, an oral Bruton's tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B cell malignancies, including chronic lymphocytic leukemia (CLL)

Francesco Forconi, Graham Collins, Emma Searle, Dima El-Sharkawi, David Lewis, Mary Gleeson, John Riches, Pam Mckay, Jeanette Doorduijn, Rogier Mous, Wendy Stevens, Sarah Injac, Kim Linton

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S53-S54
Number of pages	2
Journal	Leukemia & lymphoma
Volume	64
Publication status	Published - 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Forconi, F., Collins, G., Searle, E., El-Sharkawi, D., Lewis, D., Gleeson, M., Riches, J., Mckay, P., Doorduijn, J., Mous, R., Stevens, W., Injac, S., & Linton, K. (2023). An ongoing first-in-human phase 1 trial of NX-5948, an oral Bruton's tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B cell malignancies, including chronic lymphocytic leukemia (CLL). Leukemia & lymphoma, 64, S53-S54.

@article{7e88879092214468bf2e0b06e05363d3,

title = "An ongoing first-in-human phase 1 trial of NX-5948, an oral Bruton's tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B cell malignancies, including chronic lymphocytic leukemia (CLL)",

author = "Francesco Forconi and Graham Collins and Emma Searle and Dima El-Sharkawi and David Lewis and Mary Gleeson and John Riches and Pam Mckay and Jeanette Doorduijn and Rogier Mous and Wendy Stevens and Sarah Injac and Kim Linton",

year = "2023",

language = "English",

volume = "64",

pages = "S53--S54",

journal = "Leukemia & lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

}

Forconi, F, Collins, G, Searle, E, El-Sharkawi, D, Lewis, D, Gleeson, M, Riches, J, Mckay, P, Doorduijn, J, Mous, R, Stevens, W, Injac, S & Linton, K 2023, 'An ongoing first-in-human phase 1 trial of NX-5948, an oral Bruton's tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B cell malignancies, including chronic lymphocytic leukemia (CLL)', Leukemia & lymphoma, vol. 64, pp. S53-S54.

An ongoing first-in-human phase 1 trial of NX-5948, an oral Bruton's tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B cell malignancies, including chronic lymphocytic leukemia (CLL). / Forconi, Francesco; Collins, Graham; Searle, Emma et al.
In: Leukemia & lymphoma, Vol. 64, 2023, p. S53-S54.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - An ongoing first-in-human phase 1 trial of NX-5948, an oral Bruton's tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B cell malignancies, including chronic lymphocytic leukemia (CLL)

AU - Forconi, Francesco

AU - Collins, Graham

AU - Searle, Emma

AU - El-Sharkawi, Dima

AU - Lewis, David

AU - Gleeson, Mary

AU - Riches, John

AU - Mckay, Pam

AU - Doorduijn, Jeanette

AU - Mous, Rogier

AU - Stevens, Wendy

AU - Injac, Sarah

AU - Linton, Kim

PY - 2023

Y1 - 2023

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:001090883600053&DestLinkType=FullRecord&DestApp=WOS_CPL

M3 - Meeting Abstract

SN - 1042-8194

VL - 64

SP - S53-S54

JO - Leukemia & lymphoma

JF - Leukemia & lymphoma

ER -

An ongoing first-in-human phase 1 trial of NX-5948, an oral Bruton's tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B cell malignancies, including chronic lymphocytic leukemia (CLL)

UN SDGs

Other files and links

Cite this